ATE430754T1 - Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren - Google Patents

Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren

Info

Publication number
ATE430754T1
ATE430754T1 AT04805706T AT04805706T ATE430754T1 AT E430754 T1 ATE430754 T1 AT E430754T1 AT 04805706 T AT04805706 T AT 04805706T AT 04805706 T AT04805706 T AT 04805706T AT E430754 T1 ATE430754 T1 AT E430754T1
Authority
AT
Austria
Prior art keywords
organophoroganic
protein kinase
kinase inhibitors
indazole derivatives
indazole
Prior art date
Application number
AT04805706T
Other languages
English (en)
Inventor
Marie-Pierre Cherrier
Francois Clerc
Alain Commercon
Patrick Mailliet
Herve Minoux
Bruno Filoche-Romme
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE430754T1 publication Critical patent/ATE430754T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/65031Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04805706T 2003-12-17 2004-12-15 Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren ATE430754T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0314778A FR2864084B1 (fr) 2003-12-17 2003-12-17 Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
PCT/FR2004/003225 WO2005058923A1 (fr) 2003-12-17 2004-12-15 Derives organophosphores des indazoles et leur utilisation comme inhibiteurs des proteines kinase

Publications (1)

Publication Number Publication Date
ATE430754T1 true ATE430754T1 (de) 2009-05-15

Family

ID=34630228

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04805706T ATE430754T1 (de) 2003-12-17 2004-12-15 Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren

Country Status (17)

Country Link
US (1) US7491710B2 (de)
EP (1) EP1732938B1 (de)
JP (1) JP4630285B2 (de)
KR (1) KR20060109942A (de)
CN (1) CN1894264A (de)
AR (1) AR046736A1 (de)
AT (1) ATE430754T1 (de)
AU (1) AU2004299299A1 (de)
BR (1) BRPI0417708A (de)
CA (1) CA2546903A1 (de)
DE (1) DE602004021037D1 (de)
FR (1) FR2864084B1 (de)
IL (1) IL176233A0 (de)
MX (1) MXPA06006832A (de)
TW (1) TW200529828A (de)
UY (1) UY28679A1 (de)
WO (1) WO2005058923A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694686A1 (de) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinaseinhibitoren
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1647549A1 (de) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazole, Benzisoxazole und Benzisothiazole mit oestrogenen Eigenschaften
EP1812439B2 (de) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
DE102004052725B4 (de) * 2004-10-27 2007-07-12 Technische Universität Chemnitz Verfahren zur Herstellung substituierter Phosphane und nach dem Verfahren hergestellte substituierte Phosphane
ES2426482T3 (es) * 2005-01-27 2013-10-23 Kyowa Hakko Kirin Co., Ltd. Inhibidor de IGF-1R
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20120329794A1 (en) 2006-06-30 2012-12-27 Kyowa Hakko Kirin Co., Ltd. Ab1 KINASE INHIBITORS
EP2036894A4 (de) 2006-06-30 2011-01-12 Kyowa Hakko Kirin Co Ltd Aurora-inhibitor
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2133095A4 (de) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd Pharmazeutische zusammensetzung
CN101440092B (zh) * 2008-12-25 2010-11-17 浙江大学 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
CN105037355B (zh) 2009-08-10 2017-06-06 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
IN2014CN02646A (de) 2011-09-14 2015-08-07 Samumed Llc
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ629282A (en) 2012-05-04 2017-04-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2943198B1 (de) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazolinhibitoren des wnt-signalwegs und therapeutische verwendungen davon
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
JP6659445B2 (ja) * 2016-04-28 2020-03-04 株式会社トクヤマ 脱ベンジル化方法
MX390577B (es) 2016-06-01 2025-03-20 Samumed Llc Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida.
JP2019535672A (ja) 2016-10-21 2019-12-12 サミュメッド リミテッド ライアビリティ カンパニー インダゾール−3−カルボキサミドの使用方法およびwnt/β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
CN114072387B (zh) * 2019-11-06 2024-03-08 暨南大学 吲唑类化合物及其药用组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT630367E (pt) * 1992-03-09 2000-10-31 Zeneca Ltd Novos arilindazoles e sua utilizacao como herbicidas
JPH09281630A (ja) * 1996-04-12 1997-10-31 Konica Corp ハロゲン化銀写真感光材料
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
FR2864084A1 (fr) 2005-06-24
CA2546903A1 (fr) 2005-06-30
US20050137171A1 (en) 2005-06-23
EP1732938B1 (de) 2009-05-06
MXPA06006832A (es) 2006-09-04
AR046736A1 (es) 2005-12-21
JP4630285B2 (ja) 2011-02-09
KR20060109942A (ko) 2006-10-23
CN1894264A (zh) 2007-01-10
UY28679A1 (es) 2005-08-31
US7491710B2 (en) 2009-02-17
FR2864084B1 (fr) 2006-02-10
WO2005058923A1 (fr) 2005-06-30
JP2007514721A (ja) 2007-06-07
BRPI0417708A (pt) 2007-03-20
AU2004299299A1 (en) 2005-06-30
IL176233A0 (en) 2006-10-05
DE602004021037D1 (de) 2009-06-18
TW200529828A (en) 2005-09-16
EP1732938A1 (de) 2006-12-20

Similar Documents

Publication Publication Date Title
ATE430754T1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE521598T1 (de) 5-phenylthiazol-derivate und ihre verwendung als pi3 kinase inhibitoren
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE60332023D1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
DE602005015699D1 (de) Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
SI1648426T1 (sl) Derivati benzimidazola in njih uporaba kot inhibitorji proteinskih kinaz
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE60221233D1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE501159T1 (de) 1-(d-glykopyranosyl)-3-(4- cyclopropylphenylmethyl)-4-halogenindolderivate und deren verwendung als sglt-inhibitoren
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
DE50311397D1 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
ATE353083T1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties